Latest news
Tissue-Agnostic Medicine Has a New Proof Point
The FDA has converted selpercatinib to traditional approval for RET fusion-positive solid tumours in adults and children. The decision strengthens tissue-agnostic precision oncology, but testing gaps still decide who is found.
IPM Brief – Issue 5 | Breakthroughs Don’t Deliver Themselves
Prostate Cancer Access Moves Into the Veterans System
Gastric Cancer Gets a New Biomarker Access Signal
The Brain Can Recover. The System Often Does Not Let It.
CIDP Treatment Moves Beyond the IVIg Default
Ebola Modelling Shows the Outbreak May Be Bigger Than the Count
Court Fight Over ACIP Turns Vaccine Advice Into an Access Risk
Metastatic Cancer Means Living With Loss Before the End
Surviving Cancer Is Not the Same as Being Recovered
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.